Pros and cons of pharmaceutical manufacturing in China and India

The current global environment is forcing all pharmaceutical companies to improve their efficiency and reduce cost. As such, almost all of them have recently made drastic changes in their business strategies, according to a new report added to the offering of Research and Markets.

They have been seeking the balances between innovative drugs and generic drugs in their product portfolios and between the developed markets and the emerging markets in their market focuses. As a result, almost all pharma companies have been gradually reducing their internal production capacities. The resulting manufacturing work has all been outsourced to third parties. It has resulted in the increasing demands for both active pharmaceutical ingredients (APIs) and dosage forms, both generics and brand names, both marketed drugs and developmental drugs, and both small molecules and biologics.

Key findings of the report